Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones
- PMID: 34854012
- DOI: 10.1007/s11033-021-07003-7
Reversal of haloperidol-induced orofacial dyskinesia and neuroinflammation by isoflavones
Abstract
Background: Schizophrenia is a mental illness and its pharmacological treatment consists in the administration of antipsychotics like haloperidol. However, haloperidol often causes extrapyramidal motor disorders such as tardive dyskinesia (TD). So far, there is no effective treatment against TD and alternatives for it have been sought. Isoflafones have been studied as neuroprotector and inhibitor of monoamine oxidase enzyme. Thus, the objective is to evaluate the possible protective effect of isoflavones against the induction of involuntary movements induced by haloperidol in an animal model.
Methods and results: Male Wistar rats were treated with haloperidol (1 mg/kg/day) and/or isoflavones (80 mg/kg) for 28 days. Rats were submitted to behavioral evaluation to quantify vacuous chewing movements (VCM) and locomotor activity. In addition, the levels of pro-inflammatory cytokines were measured in the striatum. Haloperidol treatment reduced the locomotor activity and increased the number of VCM in rats. Co-treatment with isoflavones was able to reverse hypolocomotion and reduce the number of VCM. Besides, haloperidol caused significant increase in the proinflammatory cytokines (interleukin-1β:IL-1β, tumor necrosis factor-α: TNF-α and IL-6 and the co-treatment with isoflavones was able to reduce the levels of IL-1β and TNF-α, but not IL-6.
Conclusions: It is believed that the beneficial effect found with this alternative treatment is related to its anti-inflammatory potential and to the action on estrogen receptors (based on scientific literature findings). Finally, further studies are needed to elucidate the mechanisms of isoflavones in reducing motor disorders induced by antipsychotics.
Keywords: Antipsychotics; Isoflavones; Neuroinflammation; Tardive dyskinesia.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.
References
-
- Ijaz S, Bolea B, Davies S, Savović J, Richards A, Sullivan S, Moran P (2018) Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews. BMC Psychiatry 18:275 - DOI
-
- Bhugra D (2005) The global prevalence of schizophrenia. PLoS Med 2:e151 - DOI
-
- Nardi AE, Quevedo J, Da Silva AG (2015) Esquizofrenia: teoria e clínica. Artmed Editora, Porto Alegre
-
- Brown MJ, Sharma P, Bennett PN (2012) Clin Pharmacol. Elsevier Health Sciences, London
-
- Amato D, Beasleyb CL, Hahn M, Vernon A (2016) Neuroadaptations to antipsychotic drugs: insights from pre-clinical and human post-mortem studies. Neurosci Biobehav 15:1–19
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
